Unmet Need for Evidence on the Possible Role of Neoadjuvant Chemotherapy in Gynecologic Malignant Disease, Volume II
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 15 October 2024 | Viewed by 1235
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue "Unmet Need for Evidence on the Possible Role of Neoadjuvant Chemotherapy in Gynecologic Malignant Disease, Volume II" (https://www.mdpi.com/journal/cancers/special_issues/Gynaecologic_Malignant_Disease).
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) can be an alternative approach to primary cytoreductive surgery in ovarian cancer. Multiple European and Asian randomized controlled trials have examined the perioperative and oncological outcomes of NACT followed by IDS for ovarian cancer, and recent meta-analyses of these trials concluded that NACT–IDS has a survival effect comparable to that of primary debulking surgery with lower perioperative morbidity and mortality. Owing to the results of recent level I evidence, the use of NACT has gradually increased in recent years. Nevertheless, the optimal NACT regimen, as well as the optimal NACT cycle course, remain undetermined.
Unlike the positive effects of NACT on the outcomes of ovarian cancer, the role of NACT in cervical cancer appears to be limited. However, the number of randomized controlled trials to assess the possible role of NACT in cervical cancer is still limited, and further studies are warranted.
As for endometrial cancer, clinical studies that examine the role of NACT in advanced endometrial cancer are scant. To the best of our knowledge, no randomized controlled study on this matter has been conducted. In this Special Issue, we focus on the unmet need for evidence on the effects of NACT on gynecological malignant diseases.
This Special Issue focuses on unresolved clinical questions regarding the possible role of NACT in gynecologic malignancies, i.e., the optimal NACT regimen and cycle course in ovarian cancer, the possible effect of NACT on cervical cancer, and the role of NACT in endometrial cancer.
Original research articles and reviews are both welcome. We look forward to your response.
Dr. Shinya Matsuzaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoadjuvant chemotherapy
- primary chemotherapy
- trends
- optimal number of cycles
- gynecological cancer
- platinum resistance
